Advances in research of rhendostatin in the treatment of cancer

doi:10.3760/cma.j.issn.1673-422X.2016.05.010

Abstract

Abstract: Recombinant human endostatin (Endostar) is a broad spectrum molecular targeted drug on antiangiogenesis that the main evidencebased data is combined chemotherapy treatment of advanced nonsmall cell lung cancer (NSCLC). In recent years, the researches of recombinant human endostatin used in the treatment of various malignant tumors are on the increase and achieve good effect. In addition, the researches about combined treatment methods, routes of administration, methods of medication are carried out gradually, which will be conducive to the reasonable application in clinical.

Key words: Neoplasms, Drug therapy, Recombinant human endostatin

Xie Wenyao, Jiang Da, Yang Zhiyong, Dong Qian. Advances in research of rhendostatin in the treatment of cancer[J]. Journal of International Oncology, 2016, 43(5): 360-363.

References

［1］ Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase Ⅲ, randomized, openlabel, firstline study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced nonsmallcell lung cancer in Asia (IPASS)［J］. J Clin Oncol, 2011, 29(21): 2866-2874. DOI:10.1200/JCO.2010.33.4235. ［2］ Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALKpositive lung cancer［J］. N Engl J Med, 2013, 368(25): 2385-2394. DOI: 10.1056/NEJMoa1214886. ［3］ Zhou C, Wu YL, Chen G, et al. Beyond: a randomized, doubleblind, placebocontrolled, multicenter, phase Ⅲ study of firstline carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous nonsmallcell lung cancer［J］. J Clin Oncol, 2015, 33(19): 2197-2204. DOI: 10.1200/JCO.2014.59.4424. ［4］ Wang J, Sun Y, Liu Y, et al. Results of randomized, multicenter, doubleblind phase Ⅲ trial of rhendostatin (YH16) in treatment of advanced nonsmall cell lung cancer patients［J］. Zhongguo Fei Ai Za Zhi, 2005, 8(4): 283-290. DOI: 10.3779/j.issn.10093419.2005.04.07. ［5］ Wang J, Sun Y, Qin S, et al. Results of phase Ⅳ clinical trial of combining endostar with chemotherapy for treatment of advanced nonsmall cell lung cancer (NSCLC)［J］. J Clin Oncol, 2010, 28(15S): abstr7598. ［6］ Robert NJ, Dieras V, Glaspy J, et al. RIBBON1: randomized, doubleblind, placebocontrolled, phase Ⅲ trial of chemotherapy with or without bevacizumab for firstline treatment of human epidermal growth factor receptor 2negative, locally recurrent or metastatic breast cancer［J］. J Clin Oncol, 2011, 29(10): 1252-1260. DOI: 10.1200/JCO.2010.28.0982. ［7］徐春凌, 梁栋. GP方案联合重组人血管内皮抑制素治疗晚期转移性乳腺癌的临床疗效［J］. 中国实用医药, 2012, 7(23): 131-132. ［8］夏欣欣, 韩黎丽, 李晓阳, 等. 重组人血管内皮抑制素联合化疗治疗晚期乳腺癌疗效观察［J］. 中华实用诊断与治疗杂志, 2014, 28(6): 621-622. ［9］ Hodi FS, O′day SJ, Mcdermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma［J］. N Engl J Med, 2010, 363(8): 711-723. DOI: 10.1056/NEJMoa1003466. ［10］ Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAFmutated melanoma［J］. N Engl J Med, 2012, 367(2): 107-114. DOI: 10.1056/NEJMoa1203421. ［11］崔传亮, 迟志宏, 袁香庆, 等. 重组人血管内皮抑制素联合化疗一线治疗晚期黑色素瘤的Ⅱ期临床研究［J］. 临床肿瘤学杂志, 2009, 14(1): 74-79. ［12］ Cui C, Mao L, Chi Z, et al. A phase Ⅱ, randomized, doubleblind, placebocontrolled multicenter trial of Endostar in patients with metastatic melanoma［J］. Mol Ther, 2013, 21(7): 1456-1463. DOI: 10.1038/mt.2013.79. ［13］ Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as firstline therapy in advanced gastric cancer: a randomized, doubleblind, placebocontrolled phase Ⅲ study［J］. J Clin Oncol, 2011, 29(30): 3968-3976. DOI: 10.1200/JCO.2011.36.2236. ［14］迪吉, 赵久达, 李瑜瑛, 等. 国产重组人血管内皮抑素联合TCF方案治疗晚期胃癌的临床观察［J］. 现代预防医学, 2012, 39(14): 3722-3724. ［15］綦晓艳, 余宗阳, 欧阳学农, 等. 重组人血管内皮抑制素联合化疗一线治疗晚期转移性结直肠癌的疗效观察［J］. 现代肿瘤医学, 2015, 7(17): 2459-2463. ［16］ Niedergethmann M, Hildenbrand R, Wostbrock B, et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas［J］. Pancreas, 2002, 25(2): 122-129. ［17］邢士超, 沈丽琴, 庄志祥. 国产吉西他滨联合重组人血管内皮抑制素二线治疗晚期胰腺癌的临床观察［J］. 临床肿瘤学杂志, 2008, 13(12): 1132-1134. ［18］柯庆华, 周世琼, 胡艳, 等. 重组人血管内皮抑制素(重组人血管内皮抑制素)联合放疗同步治疗中晚期宫颈癌48例的近期疗效［J］. 现代肿瘤医学, 2011, 19(10): 2066-2068. ［19］刘荣强, 张淑芳. 重组人血管内皮抑制素联合三维适形放疗治疗局部晚期非小细胞肺癌的临床疗效［J］. 实用临床医药杂志, 2014, 18(16): 75-77. ［20］鲁士均. 自噬在重组人血管内皮抑制素与厄洛替尼对A549细胞体外抑制中的作用研究［D］ . 苏州: 苏州大学, 2011. ［21］ Niu N, Li B, Liu C, et al. Combining bevacizumab with endostatin gets better antitumor efficacy in vivo in lung cancer animal model［J］. Zhongguo Fei Ai Za Zhi, 2013, 16(2): 61-66. DOI: 10.3779/j.issn.10093419.2013.02.01. ［22］ Meng MB, Jiang XD, Deng L, et al. Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: experimental and clinical evidence［J］. Radiother Oncol, 2013, 106(1): 130-137. DOI: 10.1016/j.radonc.2012.10.022. ［23］苏煜, 周志鸿, 王强. 肝动脉化疗栓塞术中注入重组人血管内皮抑制素治疗中晚期肝癌的疗效及安全性分析［J］. 实用肝脏病杂志, 2014, 17(6): 644-646. ［24］张弢, 段学章, 张军华, 等. 重组人血管内皮抑制素(重组人血管内皮抑制素)联合肝动脉栓塞化疗术(TACE)治疗中晚期肝癌的临床疗效评价［J］. 现代生物医学进展, 2014, 14(34): 6664-6666. ［25］杨剑, 卢伟, 蒋富强, 等. 重组人血管内皮抑制素联合血管介入治疗难治性晚期肺癌的临床研究［J］. 现代仪器与医疗, 2015, 21(3): 27-29. ［26］沈清, 顾爱琴, 武建毅, 等. 重组人血管内皮抑制素联合顺铂治疗非小细胞肺癌恶性胸腔积液疗效观察［J］. 实用临床医药杂志, 2012, 16(5): 29-31. ［27］姜贻乾, 黄常新, 李朝阳, 等. 重组人血管内皮抑素联合顺铂腹腔灌注治疗恶性腹水的临床观察［J］. 现代肿瘤医学, 2012, 20(2): 339-341. ［28］ Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition［J］. J Clin Invest, 2006, 116(10): 2610-2621. DOI: 10.1172/JCI24612. ［29］庞林荣, 陈俊, 陆静尔, 等. 重组人血管内皮抑制素不同给药方法联合GP方案治疗晚期非小细胞肺癌临床研究［J］. 现代实用医学, 2015, 27(2): 255-256, 276. ［30］黄岩.不同剂量内皮抑素持续静脉泵注给药治疗NSCLC的研究探索［R］. CSCO: 抗肿瘤血管靶向治疗国际论坛, 2015. ［31］聂学诚, 种道群, 邱泗安, 等. 晚期非小细胞肺癌血管正常化时化疗的临床观察［J］. 临床肿瘤学杂志, 2012, 17(7): 648-651.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.